China TCM Wins Shareholder Approval for 2026–2028 Financial, Purchase and Supply Frameworks

China Traditional Chinese Medicine Holdings Co ( (HK:0570) ) has shared an update.

China Traditional Chinese Medicine Holdings Co. Limited announced that all resolutions put to shareholders at its extraordinary general meeting on 2 February 2026 were duly passed by poll. Shareholders approved, confirmed and ratified the company’s 2026–2028 Financial Services Framework Agreement, as well as new Master Purchase and Master Supply Agreements and their respective annual caps for the three financial years ending 31 December 2028, despite major shareholder CNPGC and its associates abstaining from voting on the relevant resolutions. The strong support for the purchase and supply arrangements, with approval rates around 99%, provides the group with formally sanctioned frameworks for intra-group financial services and trading activities over the next three years, underpinning operational continuity and related-party transactions in line with Hong Kong listing requirements.

The most recent analyst rating on (HK:0570) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.

More about China Traditional Chinese Medicine Holdings Co

China Traditional Chinese Medicine Holdings Co. Limited is a Hong Kong-incorporated company listed on the Hong Kong Stock Exchange, operating in the traditional Chinese medicine sector. It is involved in the manufacturing, supply and distribution of traditional Chinese medicine products and related services, serving healthcare and consumer markets in China and potentially other regions through its listed platform.

YTD Price Performance: -1.44%

Average Trading Volume: 13,339,631

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$10.37B

Learn more about 0570 stock on TipRanks’ Stock Analysis page.